HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon

Review the latest data and expert guidance to enhance treatment of your patients with HER2-positive MBC! This comprehensive program features a text-based educational module with downloadable slides and focused clinical commentaries on recent advances and emerging research.

Share

Program Content

Activities

New Agents for HER2+ MBC
How I Plan to Use Trastuzumab Deruxtecan and Tucatinib in My Practice
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 21, 2020

Expires: January 19, 2021

CNS Mets in HER2+ MBC
How I Approach CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 29, 2020

Expires: April 28, 2021

Activities

HER2+ MBC Slides
HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2020

Expires: April 12, 2021

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen